157 related articles for article (PubMed ID: 15928917)
21. Exploration of a binding mode of benzothiazol-2-yl acetonitrile pyrimidine core based derivatives as potent c-Jun N-terminal kinase-3 inhibitors and 3D-QSAR analyses.
Sharma P; Ghoshal N
J Chem Inf Model; 2006; 46(4):1763-74. PubMed ID: 16859308
[TBL] [Abstract][Full Text] [Related]
22. Comparative QSAR modeling of CCR5 receptor binding affinity of substituted 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas.
Thomas Leonard J; Roy K
Bioorg Med Chem Lett; 2006 Sep; 16(17):4467-74. PubMed ID: 16806923
[TBL] [Abstract][Full Text] [Related]
23. Molecular modelling studies for the discovery of new substituted pyridines derivatives with angiotensin II AT1 receptor antagonists.
Sharma MC
Interdiscip Sci; 2014 Sep; 6(3):197-207. PubMed ID: 25205497
[TBL] [Abstract][Full Text] [Related]
24. Pyrimidine derivatives as potent and selective A3 adenosine receptor antagonists.
Yaziji V; Rodríguez D; Gutiérrez-de-Terán H; Coelho A; Caamaño O; García-Mera X; Brea J; Loza MI; Cadavid MI; Sotelo E
J Med Chem; 2011 Jan; 54(2):457-71. PubMed ID: 21186795
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological activities of 4-phenyl-5-pyridyl-1,3-thiazole derivatives as selective adenosine A3 antagonists.
Miwatashi S; Arikawa Y; Matsumoto T; Uga K; Kanzaki N; Imai YN; Ohkawa S
Chem Pharm Bull (Tokyo); 2008 Aug; 56(8):1126-37. PubMed ID: 18670113
[TBL] [Abstract][Full Text] [Related]
26. A Structure-Activity Relationship Study of Imidazole-5-Carboxylic Acid Derivatives as Angiotensin II Receptor Antagonists Combining 2D and 3D QSAR Methods.
Sharma MC
Interdiscip Sci; 2016 Mar; 8(1):1-10. PubMed ID: 26202941
[TBL] [Abstract][Full Text] [Related]
27. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors.
Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
Drug Metab Dispos; 2000 Aug; 28(8):994-1002. PubMed ID: 10901712
[TBL] [Abstract][Full Text] [Related]
28. QSAR studies of CYP2D6 inhibitor aryloxypropanolamines using 2D and 3D descriptors.
Roy PP; Roy K
Chem Biol Drug Des; 2009 Apr; 73(4):442-55. PubMed ID: 19291105
[TBL] [Abstract][Full Text] [Related]
29. Four-dimensional quantitative structure-activity relationship analysis of a series of interphenylene 7-oxabicycloheptane oxazole thromboxane A2 receptor antagonists.
Albuquerque MG; Hopfinger AJ; Barreiro EJ; de Alencastro RB
J Chem Inf Comput Sci; 1998; 38(5):925-38. PubMed ID: 9770304
[TBL] [Abstract][Full Text] [Related]
30. Linear and nonlinear 3D-QSAR approaches in tandem with ligand-based homology modeling as a computational strategy to depict the pyrazolo-triazolo-pyrimidine antagonists binding site of the human adenosine A2A receptor.
Michielan L; Bacilieri M; Schiesaro A; Bolcato C; Pastorin G; Spalluto G; Cacciari B; Klotz KN; Kaseda C; Moro S
J Chem Inf Model; 2008 Feb; 48(2):350-63. PubMed ID: 18215030
[TBL] [Abstract][Full Text] [Related]
31. QSAR of antilipid peroxidative activity of substituted benzodioxoles using chemometric tools.
Mitra I; Roy K; Saha A
J Comput Chem; 2009 Dec; 30(16):2712-22. PubMed ID: 19399769
[TBL] [Abstract][Full Text] [Related]
32. QSAR modeling of toxicity of diverse organic chemicals to Daphnia magna using 2D and 3D descriptors.
Kar S; Roy K
J Hazard Mater; 2010 May; 177(1-3):344-51. PubMed ID: 20045248
[TBL] [Abstract][Full Text] [Related]
33. How good are ensembles in improving QSAR models? The case with eCoRIA.
Khedkar VM; Joseph J; Pissurlenkar R; Saran A; Coutinho EC
J Biomol Struct Dyn; 2015; 33(4):749-69. PubMed ID: 24754910
[TBL] [Abstract][Full Text] [Related]
34. Docking and 3D-QSAR studies of diverse classes of human aromatase (CYP19) inhibitors.
Roy PP; Roy K
J Mol Model; 2010 Oct; 16(10):1597-616. PubMed ID: 20195667
[TBL] [Abstract][Full Text] [Related]
35. Novel thiazole-thiophene conjugates as adenosine receptor antagonists: synthesis, biological evaluation and docking studies.
Pandya DH; Sharma JA; Jalani HB; Pandya AN; Sudarsanam V; Kachler S; Klotz KN; Vasu KK
Bioorg Med Chem Lett; 2015 Mar; 25(6):1306-9. PubMed ID: 25686851
[TBL] [Abstract][Full Text] [Related]
36. Docking and 3D QSAR studies of protoporphyrinogen oxidase inhibitor 3H-pyrazolo[3,4-d][1,2,3]triazin-4-one derivatives.
Roy K; Paul S
J Mol Model; 2010 Jan; 16(1):137-53. PubMed ID: 19543755
[TBL] [Abstract][Full Text] [Related]
37. Comparative molecular field analysis (coMFA) study of epothilones-tubulin depolymerization inhibitors: pharmacophore development using 3D QSAR methods.
Lee KW; Briggs JM
J Comput Aided Mol Des; 2001 Jan; 15(1):41-55. PubMed ID: 11217918
[TBL] [Abstract][Full Text] [Related]
38. Predictive QSAR modeling of HIV reverse transcriptase inhibitor TIBO derivatives.
Mandal AS; Roy K
Eur J Med Chem; 2009 Apr; 44(4):1509-24. PubMed ID: 18760864
[TBL] [Abstract][Full Text] [Related]
39. Ligand-based prediction of active conformation by 3D-QSAR flexibility descriptors and their application in 3+3D-QSAR models.
Martinek TA; Otvös F; Dervarics M; Tóth G; Fülöp F
J Med Chem; 2005 May; 48(9):3239-50. PubMed ID: 15857130
[TBL] [Abstract][Full Text] [Related]
40. 3D-QSAR studies on chromone derivatives as HIV-1 protease inhibitors: application of molecular field analysis.
Nunthanavanit P; Anthony NG; Johnston BF; Mackay SP; Ungwitayatorn J
Arch Pharm (Weinheim); 2008 Jun; 341(6):357-64. PubMed ID: 18442018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
